Meeting
2023 ASCO Annual Meeting
A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
Authors
Colin R Lindsay
The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom
Colin R Lindsay , Rajwanth Veluswamy , Gilberto Castro Jr., Daniel Shao-Weng Tan , Rafael Caparica , Sabine Glaser , Shweta Malhotra , Aislyn Boran , Enriqueta Felip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05445843
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9158)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9158
Abstract #
TPS9158
Poster Bd #
136b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
First Author: Hina Khan
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
First Author: Rachel Frascati